A fundamental property of malignant tumors is increased glucose metabolism, which can be estimated by imaging the glucose analog fluorodeoxyglucose (FDG). The aim of this study was to determine whether FDG uptake in lung carcinoma, as measured on positron emission tomography (PET) imaging in patient
Positron emission tomography imaging in nonsmall-cell lung cancer
β Scribed by Jeremy J. Erasmus; Homer A. Macapinlac; Stephen G. Swisher
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 537 KB
- Volume
- 110
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Positron emission tomography (PET) using 18Fβ2βdeoxyβDβglucose, a Dβglucose analog labeled with fluorineβ18, complements conventional radiologic assessment in the evaluation of patients with nonsmallβcell lung cancer (NSCLC). PET is being routinely used to improve the detection of nodal and extrathoracic metastases. PET is also currently being evaluated in the assessment of prognosis and therapeutic response and by potentially allowing an earlier assessment of response may prove invaluable in the oncologic management of patients. The article discusses the diagnosis, staging, and assessment of treatment response and prognosis with an emphasis on the appropriate clinical use of PET in management. Cancer 2007. Β© 2007 American Cancer Society.
π SIMILAR VOLUMES
## BACKGROUND. It is common protocol in radionuclide therapies to administer a Yusuf E
## Abstract ## BACKGROUND: The authors studied growth and progression of untreated nonsmall cell lung cancer (NSCLC) by comparing diagnostic and radiotherapy (RT) planning fluorodeoxyglucose (FDG)βpositron emission tomography (PET)/computed tomography (CT) scans before proposed radical chemoβRT.